JP7067725B2 - Ａｃｃ阻害剤としての新規な化合物およびそれらの使用 - Google Patents

Ａｃｃ阻害剤としての新規な化合物およびそれらの使用 Download PDF

Info

Publication number
JP7067725B2
JP7067725B2 JP2020524667A JP2020524667A JP7067725B2 JP 7067725 B2 JP7067725 B2 JP 7067725B2 JP 2020524667 A JP2020524667 A JP 2020524667A JP 2020524667 A JP2020524667 A JP 2020524667A JP 7067725 B2 JP7067725 B2 JP 7067725B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
compound according
haloalkyl
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2020524667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527175A (ja
JP2020527175A5 (https=
Inventor
ジャン，ジュンボ
リャオ，ホン
ワン，ペイペイ
ワン，ポン
Original Assignee
ナンジン ルイジエ ファーマテック カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナンジン ルイジエ ファーマテック カンパニー， リミテッド filed Critical ナンジン ルイジエ ファーマテック カンパニー， リミテッド
Publication of JP2020527175A publication Critical patent/JP2020527175A/ja
Publication of JP2020527175A5 publication Critical patent/JP2020527175A5/ja
Application granted granted Critical
Publication of JP7067725B2 publication Critical patent/JP7067725B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020524667A 2017-07-17 2018-07-17 Ａｃｃ阻害剤としての新規な化合物およびそれらの使用 Expired - Fee Related JP7067725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/093106 2017-07-17
CNPCT/CN2017/093106 2017-07-17
PCT/CN2018/095973 WO2019015583A1 (en) 2017-07-17 2018-07-17 NOVEL COMPOUNDS AND THEIR USES AS ACC INHIBITORS

Publications (3)

Publication Number Publication Date
JP2020527175A JP2020527175A (ja) 2020-09-03
JP2020527175A5 JP2020527175A5 (https=) 2021-07-26
JP7067725B2 true JP7067725B2 (ja) 2022-05-16

Family

ID=65014996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524667A Expired - Fee Related JP7067725B2 (ja) 2017-07-17 2018-07-17 Ａｃｃ阻害剤としての新規な化合物およびそれらの使用

Country Status (5)

Country Link
US (1) US10995099B2 (https=)
EP (1) EP3655409B1 (https=)
JP (1) JP7067725B2 (https=)
CN (1) CN111201234A (https=)
WO (2) WO2019015583A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019020041A1 (zh) * 2017-07-26 2019-01-31 南京圣和药业股份有限公司 作为acc抑制剂的化合物及其应用
EP3995498A4 (en) 2019-07-02 2023-03-01 Sunshine Lake Pharma Co., Ltd. THIENOPYRIMIDI DERIVATIVES WITH STEREO CONFIGURATION AND THEIR USE IN MEDICINE
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
JP7612682B2 (ja) 2019-10-15 2025-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なテトラゾール
CN112778325A (zh) * 2019-11-07 2021-05-11 南京瑞捷医药科技有限公司 一种acc抑制剂及其用途
JP7565439B2 (ja) * 2020-10-14 2024-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｒｐａ１阻害剤としてのテトラゾール誘導体
WO2022079091A1 (en) * 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Tetrazole derivatives as trpa1 inhibitors
TW202233632A (zh) * 2021-02-07 2022-09-01 大陸商正大天晴藥業集團股份有限公司 噻吩并嘧啶衍生物
CA3210965A1 (en) 2021-04-14 2022-10-20 Boehringer Ingelheim International Gmbh 3h,4h-thieno[2,3-d]pyrimidin-4-one derivatives as trpa1 inhibitors
CN114409664B (zh) * 2021-12-24 2023-07-18 河北威远生物化工有限公司 一种螺杂环四氢吡喃化合物及其制备方法和应用
CN114815020B (zh) * 2022-04-21 2023-09-22 岭南师范学院 一种高品质因数折射率传感器的设计方法及折射率传感器
CN116747321B (zh) * 2023-06-14 2025-09-05 厦门君德医药科技有限公司 一种接枝改性的介孔二氧化硅及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533281A (ja) 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
WO2016112305A1 (en) 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
WO2017091600A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
WO2017091617A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Triazole acc inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ701495A (en) * 2012-05-30 2016-11-25 Bayer Cropscience Ag Compositions comprising a biological control agent and an insecticide
AU2014262547A1 (en) * 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2015003879A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicylic derivatives
CN103923084B (zh) * 2014-01-29 2016-08-17 苏州晶云药物科技有限公司 几种晶型及其制备方法
GB201419102D0 (en) * 2014-10-27 2014-12-10 Imp Innovations Ltd Novel compounds
CN205115664U (zh) * 2015-10-15 2016-03-30 阳光能源（青海）有限公司 一种用于单晶炉的二次填料装置
CN106137971A (zh) * 2015-11-17 2016-11-23 南京瑞捷医药科技有限公司 一种他克莫司分散体及其缓释组合物及制备方法
CN119977993A (zh) 2016-03-02 2025-05-13 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
EP4273132A3 (en) * 2017-03-03 2024-01-10 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
WO2018228369A1 (zh) * 2017-06-15 2018-12-20 浙江海正药业股份有限公司 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途
WO2019020041A1 (zh) * 2017-07-26 2019-01-31 南京圣和药业股份有限公司 作为acc抑制剂的化合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533281A (ja) 2011-11-11 2014-12-11 ニンバス アポロ， インコーポレイテッド Ａｃｃ阻害剤およびその使用
WO2016112305A1 (en) 2015-01-09 2016-07-14 Nimbus Apollo, Inc. Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
WO2017091600A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
WO2017091617A1 (en) 2015-11-25 2017-06-01 Gilead Apollo, Llc Triazole acc inhibitors and uses thereof

Also Published As

Publication number Publication date
EP3655409A1 (en) 2020-05-27
CN111201234A (zh) 2020-05-26
EP3655409B1 (en) 2023-12-27
WO2019015583A1 (en) 2019-01-24
JP2020527175A (ja) 2020-09-03
US10995099B2 (en) 2021-05-04
WO2020015343A1 (en) 2020-01-23
US20200140454A1 (en) 2020-05-07
EP3655409A4 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
JP7067725B2 (ja) Ａｃｃ阻害剤としての新規な化合物およびそれらの使用
JP7184988B2 (ja) チエノピリミジンジオンａｃｃ阻害剤の固体形態およびその生成のための方法
EP2964225B1 (en) CaMKII INHIBITORS AND USES THEREOF
WO2020102616A1 (en) Acly inhibitors and uses thereof
HK40110261A (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
HK40002905B (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
HK40002905A (en) Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200204

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20200204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210430

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220418

R150 Certificate of patent or registration of utility model

Ref document number: 7067725

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees